View Older Stories View More Recent Stories

Sep 21, 2018 06:00PM Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression
Sep 16, 2018 06:01PM First Randomized Controlled Trial in Portopulmonary Hypertension Shows OPSUMIT® (macitentan) Significantly Improved Pulmonary Vascular Resistance Compared with Placebo
Sep 4, 2018 08:00AM Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression
Jun 26, 2018 08:00AM Champions of Science: The Art of Ending Stigma Project Launches to Combat Stigma About Mental Illnesses Through Education and Artistic Creation
Jun 21, 2018 11:43AM Tennis Star Madison Keys Partners with ACUVUE Brand Contact Lenses
Jun 18, 2018 08:29AM Johnson & Johnson Vision (JNJ) Says FDA Approved Next Generation of Customized LASIK Treatment with iDESIGN Refractive Studio
Jun 18, 2018 08:27AM FDA Approves the Next Generation of Customized LASIK Treatment with iDESIGN Refractive Studio
Jun 6, 2018 04:46PM Johnson & Johnson Announces Binding Offer from Fortive Corporation to Acquire Advanced Sterilization Products (ASP)
May 30, 2018 08:12AM Janssen (JNJ) Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for Treatment of MM
May 30, 2018 08:00AM Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for the Treatment of Multiple Myeloma
May 7, 2018 05:42AM Johnson & Johnson's (JNJ) Janssen Pharma Announces Results from Two Phase 3 Clinical Studies of Esketamine Nasal Spray
May 5, 2018 08:00AM New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression
May 1, 2018 08:14AM Johnson & Johnson (JNJ) Highlights New Studies Revealing Antioxidant Properties of Ultraviolet Blocker in ACUVUE Brand Contact Lenses
May 1, 2018 08:00AM Johnson & Johnson Vision Presents New Data on Silicone Hydrogel Contact Lens Muco-Adhesive Properties
May 1, 2018 08:00AM Johnson & Johnson Vision Presents New Studies Revealing Antioxidant Properties of Ultraviolet Blocker in ACUVUE® Brand Contact Lenses
Apr 17, 2018 09:22AM Pre-Open Movers 04/17: (RNDA) (ROKU) (NFLX) Higher; (BLCM) (LADR) (SEAC) Lower (more...)
Apr 16, 2018 07:31AM Amarantus Appoints Michael T. Ropacki, PhD as Chief Medical Advisor for Alzheimer's Blood Diagnostic LymPro Test Program
Apr 11, 2018 07:58AM Johnson & Johnson Vision Announces Revolutionary Contact Lens Innovation with ACUVUE OASYS® with Transitions® Light Intelligent Technology™
Mar 29, 2018 07:05AM Motus GI Announces 2017 Financial Results and Provides Business Outlook
Mar 15, 2018 08:37AM BabyCenter® Announces Winners of 2018 Moms' Picks Awards
Mar 5, 2018 10:00AM BabyCenter® and Collage Group Release Results of New Study "Futurecasting Families: Early Insights into Generation Z & the Future of Parenting"
Jan 9, 2018 08:15AM New Absorbable Adjunctive Hemostat From Ethicon Helps Surgeons Control Disruptive Bleeding More Efficiently
Jan 3, 2018 08:00AM Landmark Schizophrenia Data That Bring Hope in Breaking the Cycle of Hospitalization and Incarceration Receive FDA Approval for Inclusion in INVEGA SUSTENNA® (paliperidone palmitate) Label
Dec 28, 2017 09:04AM Janssen Research & Development LLC (JNJ) Reports Publication of Esketamine Phase 2 Data Showed Significant Improvement of Depressive Symptoms in People with Treatment-Resistant Depression
Dec 28, 2017 09:00AM Esketamine Phase 2 Data Published in JAMA Psychiatry Showed Significant Improvement of Depressive Symptoms in People with Treatment-Resistant Depression
Dec 21, 2017 05:03PM Janssen Biotech Inc. (JNJ) Announces Worldwide Collaboration & Licensing Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy
Dec 21, 2017 05:00PM Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy
Dec 21, 2017 08:01AM Janssen (JNJ) Reports U.S. FDA Grants Priority Review for Apalutamide as Treatment for Non-Metastatic Castration-Resistant Prostate Cancer
Dec 21, 2017 08:00AM U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer
Dec 12, 2017 07:48AM Janssen (JNJ) Presents Data Showing DARZALEX Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Dec 12, 2017 07:45AM DARZALEX® (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Dec 12, 2017 07:33AM Actinium Pharma (ATNM) Reports Promising Data on Labeling of Daratumumab with Radioisotope Actinium-225
Dec 12, 2017 05:59AM Janssen Research & Development (JNJ) Highlights New Data from Phase 1b PAVO Clinical Study Demonstrating Subcutaneous Delivery of DARZALEX (daratumumab)
Dec 11, 2017 05:15PM New Data for DARZALEX® (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma
Dec 11, 2017 08:31AM Janssen (JNJ) Submits sNDA to FDA Seeking New Indications for XARELTO for Patients with CAD/PAD
Dec 11, 2017 08:30AM Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO® (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
Dec 11, 2017 06:19AM Janssen Research & Development (JNJ) Reports Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5-Yr Follow-Up Data of IMBRUVICA (ibrutinib)
Dec 9, 2017 12:05PM Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3½-Year Follow-Up Data of IMBRUVICA® (ibrutinib)
Dec 6, 2017 08:04AM Genomic Health (GHDX) Reports Research Collaboration with Janssen Pharmaceuticals (JNJ) to Evaluate the Oncotype DX
Dec 5, 2017 08:11AM Janssen Research & Development, LLC (JNJ) Reports Phase 3 Study Evaluating IMBRUVICA (ibrutinib) in Combination with Rituximab in Waldenstrom's Macroglobulinemia Met Primary Endpoint
Dec 5, 2017 08:05AM Phase 3 Study Evaluating IMBRUVICA® (ibrutinib) in Combination with Rituximab in Waldenström's Macroglobulinemia Met Primary Endpoint
Nov 29, 2017 08:30AM BabyCenter® Reveals Top Baby Names Of 2017
Nov 21, 2017 11:41AM Janssen (JNJ) Submits Supplemental Biologics License Application to FDA to Expand Indication for DARZALEX (daratumumab)
Nov 21, 2017 11:37AM Janssen Submits Application to U.S. FDA to Expand Indication for DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma who are Transplant Ineligible
Nov 13, 2017 03:31PM Blood Pressure Control Achieved With Fewer Or No Medications Within One Month Of Bariatric Surgery And Maintained Over 12 Months
Nov 10, 2017 08:30AM Ethicon's BIOPATCH® Protective Disk with CHG Meets New CDC Recommendation and Continues as the Standard of Care to Reduce Intravascular Catheter-related Blood Stream Infections
Nov 7, 2017 08:15AM Janssen (JNJ) Says New Phase 2 Data Show Treatment With TREMFYA Improved Psoriatic Arthritis Symptoms Through One Year
Nov 7, 2017 08:00AM New Phase 2 Data Show Treatment With TREMFYA® (guselkumab) Improved Psoriatic Arthritis Symptoms Through One Year
Nov 6, 2017 08:02AM Janssen's (JNJ) STELARA Shows Positive Results in Treatment of Systemic Lupus Erythematosus in Phase 2 Trial
Nov 6, 2017 08:00AM STELARA® (ustekinumab) Shows Positive Results In Treatment Of Systemic Lupus Erythematosus In Phase 2 Trial
View More Recent Stories View Older Stories